Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Patients who are diagnosed as gastric cancer.~* No prior treatment for gastric cancer.~* Negative or unknown for HER2 testing.~* ECOG performance status of 0 or 1.~Key Exclusion Criteria:~* Unmanageable diarrhea.~* Current peripheral sensory neuropathy or paresthesia.~* Pregnant or lactating female.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAS-118/Oxaliplatin (Type: EXPERIMENTAL): TAS-118 plus Oxaliplatin
- S-1/Cisplatin (Type: ACTIVE_COMPARATOR): S-1 plus Cisplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).